1,275
Participants
Start Date
April 27, 2023
Primary Completion Date
July 2, 2024
Study Completion Date
December 18, 2024
F2C22C/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22A/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22B/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22C/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22D/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2B22E/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22A/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22B/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22C/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22D/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
F2F22E/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
Control 1
Control vaccine was administered intramuscularly in Phase 1, at Day 1.
F2F23D/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
F2F23A/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
F2F23B/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
Control 2
Control vaccine was administered intramuscularly in Phase 2, at Day 1.
F2F23C/DL001Z-NH
Study intervention was administered intramuscularly in Phase 2, at Day 1.
Control 3
Control vaccine was administered intramuscularly in Phase 2, at Day 1.
F2F22F/DL001Z
Study intervention was administered intramuscularly in Phase 1, at Day 1.
GSK Investigational Site, Tembisa
GSK Investigational Site, Antwerp
GSK Investigational Site, Johannesburg
GSK Investigational Site, Edegem
GSK Investigational Site, Mechelen
GSK Investigational Site, Buffalo
GSK Investigational Site, Cape Town
GSK Investigational Site, Ieper
GSK Investigational Site, Ghent
GSK Investigational Site, Zwalm
GSK Investigational Site, Kluisbergen
GSK Investigational Site, Syracuse
GSK Investigational Site, Rochester
GSK Investigational Site, Norfolk
GSK Investigational Site, Newport News
GSK Investigational Site, Greensboro
GSK Investigational Site, Raleigh
GSK Investigational Site, Wilmington
GSK Investigational Site, Hialeah
GSK Investigational Site, Dayton
GSK Investigational Site, Miami
GSK Investigational Site, Knoxville
GSK Investigational Site, Lexington
GSK Investigational Site, Valparaiso
GSK Investigational Site, Houston
GSK Investigational Site, Dearborn
GSK Investigational Site, Chicago
GSK Investigational Site, Lenexa
GSK Investigational Site, Wichita
GSK Investigational Site, Papillion
GSK Investigational Site, Fort Worth
GSK Investigational Site, Tomball
GSK Investigational Site, Denver
GSK Investigational Site, Boston
GSK Investigational Site, East Greenwich
GSK Investigational Site, Tielt
GSK Investigational Site, Halifax
GSK Investigational Site, Truro
GSK Investigational Site, Chicoutimi
GSK Investigational Site, Québec
GSK Investigational Site, Sherbrooke
Lead Sponsor
Collaborators (1)
CureVac
INDUSTRY
GlaxoSmithKline
INDUSTRY